Assistance Publique Hopitaux De Paris
- Address
- lock Available on a paid plan
Hematologic Malignancies and Pediatric Oncology
At Assistance Publique Hopitaux De Paris, the service d’hémato-immunologie is active in neoplasms research focused on lymphoma and acute lymphoblastic leukemia. These studies are designed to test new treatment options and better understand how to improve outcomes for children, adolescents, and young adults with difficult-to-treat blood cancers.
- Recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma
- Relapsed or refractory B-cell acute lymphoblastic leukemia
- Pediatric CD22-positive acute lymphoblastic leukemia
Research here includes evaluating novel immunotherapies and targeted approaches to improve treatment effectiveness and disease control in relapsed or resistant disease.
Immune System and Infection Prevention
This site also contributes to immune system diseases research, with studies aimed at protecting vulnerable pediatric patients from infection. The work focuses on improving prevention strategies for children whose immune defenses are weakened by illness or treatment.
- Prevention of herpes zoster in immunocompromised subjects aged 1 to 17 years
The main goal is to assess the safety and immune response of a preventive vaccine approach in young immunocompromised participants.
Cardiovascular Disease in Children
Clinical trials at Assistance Publique Hopitaux De Paris include cardiovascular diseases research centered on pediatric heart failure. These studies are designed to evaluate whether new therapies can help improve heart function and support better symptom control in children with systolic dysfunction.
- Heart failure due to systemic left ventricular systolic dysfunction
The research is focused on comparing treatment effectiveness and monitoring safety in a pediatric population with serious cardiac disease.
Digestive System Disease and Pediatric Inflammatory Bowel Disease
Another area of activity is digestive system diseases, especially ulcerative colitis in children and adolescents. The trials aim to improve disease control, reduce symptoms, and evaluate how well new therapies are tolerated in younger patients with active inflammatory bowel disease.
- Ulcerative colitis
At this Paris-based hospital, the research is centered on assessing the effectiveness, safety, and overall clinical benefit of treatment options for pediatric patients with moderate to severe disease.
Broader Hemic and Lymphatic Disease Research
The site’s hemic and lymphatic diseases portfolio reflects a strong focus on advanced therapies for challenging blood disorders. Investigators are studying new treatment strategies intended to improve remission rates, support patients after prior therapy failure, and expand options for relapsed or refractory disease.
- Refractory hematologic cancers
- Relapsed leukemia
- Pediatric and young adult lymphoma
These studies aim to build evidence for more effective and better-tolerated therapies in complex pediatric and young adult populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Cellectis1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Assistance Publique Hopitaux De Paris
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR) | Merck Sharp & Dohme LLC | Phase IV | Recruiting | Mar 2023 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alemtuzumab | 1 | Unknown | 2025-11-26 | 2025-11-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.